| API Access | |

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from Daito Pharmaceutical Co.,Ltd. was processed by Pulse News Wire on April 10, 2026. It represents a primary source document for Japanese Earnings sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Daito Pharmaceutical Reports Q3 Revenue of 36.7 billion, Up 0%

TOKYO, Apr 10 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) reported consolidated results for Q3 FY2026 (ending May 2026). Revenue was ¥36.7 billion (+0.3% YoY). operating profit was ¥2,

View all Daito Pharmaceutical Co.,Ltd. disclosures →

Daito Pharmaceutical Co.,Ltd. [4577.T]

TOKYO, Apr 10 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) reported consolidated results for Q3 FY2026 (ending May 2026).

Revenue was ¥36.7 billion (+0.3% YoY). operating profit was ¥2,751 million (+47.2%). net profit attributable to shareholders was ¥2,267 million (+86.2%).

Total assets stood at ¥75.0 billion with an equity ratio of 69.7%. The company declared an annual dividend of ¥20 per share. The full-year forecast for the current fiscal year is revenue of ¥51.0 billion (+0.7%).

Original Disclosure (PDF)

🟢 Confidence: High AI-translated content.

Daito Pharmaceutical Reports Q3 Revenue of 36.7 billion, Up 0%

Related Disclosures